Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
New Post
SEC adopts final rule that requires foreign insiders to disclose beneficial ownership positions
March 3, 2026
News Alert
SEC reaches insider trading settlements with two private pilots of British billionaire investor Joseph Lewis
February 16, 2026
News Alert
SEC reaches settlement with former day-trader to resolve insider trading charges
February 12, 2026
News Alert